Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to
grow and spread more slowly. It may also stop the growth of tumor cells in bone.
PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients
with advanced prostate cancer and bone metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University Wake Forest University Health Sciences